Telix Pharmaceuticals (TLX) said Tuesday that it has selected Cardinal Health (CAH) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatment of prostate cancer in the US.
The company said it wants to enable availability across a wide range of US locations following the recent US Food and Drug Administration approval of Gozellix and in preparation for its commercial launch during the first half of 2025.
Cardinal Health will operate as a strategic radiopharmacy distributor for Gozellix alongside Telix's in-house radiopharmacy network, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.